1.470USD-21.18%Mkt Cap: 101.19M USDP/E: —Last update: 2026-06-01
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like …
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap101.19M USD
Enterprise Value84.49M USD
Revenue (TTM)525.00K USD
Gross Profit-31.09M USD
Net Income (TTM)-45.85M USD
Revenue/Share0.0080 USD
Last Price1.470 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees30
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS14147L1089
Valuation
P/E (Trailing)—
P/E (Forward)-2.33
PEG—
EV/EBITDA-1.79
EV/Revenue160.94
P/S247.43
P/B3.74
EPS (TTM)-0.67
EPS (Forward)-0.82
52W Range
1.4002% of range4.560
52W High4.560 USD
52W Low1.400 USD
Profitability
Gross Margin0.00%
Oper. Margin-31341.46%
EBITDA Margin0.00%
Profit Margin-7732.04%
ROE-101.02%
ROA-74.09%
Growth
Revenue Growth-62.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-37.92M USD
CapEx (TTM)44.00K USD
FCF Margin-3813.62%
FCF Yield-19.79%
Net Debt-45.41M USD
Net Debt/EBITDA0.96
Balance Sheet
Debt/Equity0.02
Current Ratio3.27
Quick Ratio3.20
Book Value/Sh0.5080 USD
Cash/Share0.6740 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateFeb 20, 2019
Splits
Last Split1:6
Split DateFeb 20, 2019
Analyst Consensus
Rating1.4 (Strong Buy)
Target (Mean)7.688 USD
Target Range2.000 USD – 12.00 USD
# Analysts8
Ownership
Shares Out.68.37M
Float66.71M
Insiders5.91%
Institutions32.86%
Short Interest
Short Ratio26.8d
Short % Float26.99%
Short % Out.26.35%
Shares Short18.02M
Short (prev mo.)18.32M
Technical
SMA 501.692 (-13.1%)
SMA 2002.085 (-29.5%)
Beta1.36
S&P 52W Chg27.94%
Avg Vol (30d)1.00M
Avg Vol (10d)1.40M
Technical Indicators
RSI (14)57.9
MACD0.0423
MACD Signal0.0249
MACD Hist.+0.0174
BB Upper1.913 USD
BB Middle1.727 USD
BB Lower1.540 USD
BB Width21.64%
ATR (14)0.1172 USD
Vol Ratio (20d)0.46x